CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares fell 2.4% during trading on Monday . The company traded as low as $2.43 and last traded at $2.65. Approximately 9,979 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 33,518 shares. The stock had previously closed at $2.72.
Wall Street Analyst Weigh In
Separately, Benchmark restated a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a research report on Thursday, October 10th.
CytoMed Therapeutics Stock Down 2.4 %
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What is an Earnings Surprise?
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-sae-logo-1200x675.png&h=54&w=95&zc=2){kind=logo}
